Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

NYHA classification for decision‐making in heart failure: Time to reassess?

2023; Elsevier BV; Volume: 25; Issue: 7 Linguagem: Inglês

10.1002/ejhf.2923

1879-0844

André Zimerman, Anderson Donelli da Silveira, Scott D. Solomon, Luís Eduardo Paim Rohde,

Cardiac electrophysiology and arrhythmias

European Journal of Heart FailureVolume 25, Issue 7 p. 929-932 Viewpoint NYHA classification for decision-making in heart failure: Time to reassess? André Zimerman, André Zimerman Post-Graduate Program in Cardiology and Cardiovascular Sciences, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil Cardiovascular Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USASearch for more papers by this authorAnderson D. da Silveira, Anderson D. da Silveira Post-Graduate Program in Cardiology and Cardiovascular Sciences, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil Cardiovascular Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, BrazilSearch for more papers by this authorScott D. Solomon, Scott D. Solomon Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USASearch for more papers by this authorLuis E. Rohde, Corresponding Author Luis E. Rohde [email protected] orcid.org/0000-0002-6557-393X Post-Graduate Program in Cardiology and Cardiovascular Sciences, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil Cardiovascular Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil Corresponding author. Cardiovascular Division, Hospital de Clinicas de Porto Alegre, Post-Graduate Program in Cardiology and Cardiovascular Sciences, Medical School, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2350, Porto Alegre RSW 90035-003, Brazil. Tel: + 55 51 33598342, Email: [email protected]Search for more papers by this author André Zimerman, André Zimerman Post-Graduate Program in Cardiology and Cardiovascular Sciences, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil Cardiovascular Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USASearch for more papers by this authorAnderson D. da Silveira, Anderson D. da Silveira Post-Graduate Program in Cardiology and Cardiovascular Sciences, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil Cardiovascular Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, BrazilSearch for more papers by this authorScott D. Solomon, Scott D. Solomon Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USASearch for more papers by this authorLuis E. Rohde, Corresponding Author Luis E. Rohde [email protected] orcid.org/0000-0002-6557-393X Post-Graduate Program in Cardiology and Cardiovascular Sciences, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil Cardiovascular Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil Corresponding author. Cardiovascular Division, Hospital de Clinicas de Porto Alegre, Post-Graduate Program in Cardiology and Cardiovascular Sciences, Medical School, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2350, Porto Alegre RSW 90035-003, Brazil. Tel: + 55 51 33598342, Email: [email protected]Search for more papers by this author First published: 01 June 2023 https://doi.org/10.1002/ejhf.2923Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1White PD, Myers MM. The classification of cardiac diagnosis. JAMA. 1921; 77: 1414–1415. https://doi.org/10.1001/jama.1921.02630440034013 10.1001/jama.1921.02630440034013 Web of Science®Google Scholar 2Muntwyler J, Abetel G, Gruner C, Follath F. One-year mortality among unselected outpatients with heart failure. Eur Heart J. 2002; 23: 1861–1866. https://doi.org/10.1053/euhj.2002.3282 10.1053/euhj.2002.3282 CASPubMedWeb of Science®Google Scholar 3Bettencourt P, Ferreira A, Dias P, Pimenta J, Friões F, Martins L, et al. Predictors of prognosis in patients with stable mild to moderate heart failure. J Card Fail. 2000; 6: 306–313. https://doi.org/10.1054/jcaf.2000.20558 10.1054/jcaf.2000.20558 CASPubMedWeb of Science®Google Scholar 4Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Ferreira JP, Zannad F, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: A comparative analysis of three randomised controlled trials. Lancet. 2020; 396: 121–128. https://doi.org/10.1016/S0140-6736(20)30748-0 10.1016/S0140-6736(20)30748-0 CASPubMedWeb of Science®Google Scholar 5Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145: e876–e894. https://doi.org/10.1161/CIR.0000000000001062 10.1161/CIR.0000000000001062 PubMedWeb of Science®Google Scholar 6 CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987; 316: 1429–1435. https://doi.org/10.1056/NEJM198706043162301 10.1056/NEJM198706043162301 PubMedWeb of Science®Google Scholar 7DeVore AD, Mi X, Thomas L, Sharma PP, Albert NM, Butler J, et al. Characteristics and treatments of patients enrolled in the CHAMP-HF registry compared with patients enrolled in the PARADIGM-HF trial. J Am Heart Assoc. 2018; 7:e009237. https://doi.org/10.1161/JAHA.118.009237 10.1161/JAHA.118.009237 CASPubMedWeb of Science®Google Scholar 8Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017; 19: 1624–1634. https://doi.org/10.1002/ejhf.945 10.1002/ejhf.945 PubMedWeb of Science®Google Scholar 9Linssen GCM, Veenis JF, Brunner-La Rocca HP, van Pol PEJ, Engelen DJM, van Tooren RM, et al.; CHECK-HF Investigators. Differences in guideline-recommended heart failure medication between Dutch heart failure clinics: An analysis of the CHECK-HF registry. Neth Heart J. 2020; 28: 334–344. https://doi.org/10.1007/s12471-020-01421-1 10.1007/s12471-020-01421-1 CASPubMedWeb of Science®Google Scholar 10Sjöland H, Silverdal J, Bollano E, Pivodic A, Dahlström U, Fu M. Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003–2015. BMC Cardiovasc Disord. 2021; 21: 307. https://doi.org/10.1186/s12872-021-02124-0 10.1186/s12872-021-02124-0 PubMedWeb of Science®Google Scholar 11Goldberg LR, Jessup M. Stage B heart failure: Management of asymptomatic left ventricular systolic dysfunction. Circulation. 2006; 113: 2851–2860. https://doi.org/10.1161/CIRCULATIONAHA.105.600437 10.1161/CIRCULATIONAHA.105.600437 PubMedWeb of Science®Google Scholar 12 SOLVD Investigators; Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327: 685–691. https://doi.org/10.1056/NEJM199209033271003 10.1056/NEJM199209033271003 PubMedWeb of Science®Google Scholar 13Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: A follow-up study. Lancet. 2003; 361: 1843–1848. https://doi.org/10.1016/S0140-6736(03)13501-5 10.1016/S0140-6736(03)13501-5 CASPubMedWeb of Science®Google Scholar 14McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993–1004. https://doi.org/10.1056/NEJMoa1409077 10.1056/NEJMoa1409077 CASPubMedWeb of Science®Google Scholar 15Raphael C, Briscoe C, Davies J, Whinnett ZI, Manisty C, Sutton R, et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart. 2007; 93: 476–482. https://doi.org/10.1136/hrt.2006.089656 10.1136/hrt.2006.089656 PubMedWeb of Science®Google Scholar 16Caraballo C, Desai NR, Mulder H, Alhanti B, Wilson FP, Fiuzat M, et al. Clinical implications of the New York Heart Association classification. J Am Heart Assoc. 2019; 8:e014240. https://doi.org/10.1161/JAHA.119.014240 10.1161/JAHA.119.014240 PubMedWeb of Science®Google Scholar 17Blacher M, Zimerman A, Engster PHB, Grespan E, Polanczyk CA, Rover MM, et al. Revisiting heart failure assessment based on objective measures in NYHA functional classes I and II. Heart. 2020; 107: 1487–1492. https://doi.org/10.1136/heartjnl-2020-317984 10.1136/heartjnl-2020-317984 PubMedWeb of Science®Google Scholar 18Zimerman A, da Silveira AD, Borges MS, Engster PHB, Schaan TU, de Souza GC, et al. Functional assessment based on cardiopulmonary exercise testing in mild heart failure: A multicentre study. ESC Heart Fail. 2023; 10: 1689–1697. https://doi.org/10.1002/ehf2.14287 10.1002/ehf2.14287 PubMedWeb of Science®Google Scholar 19Rohde LE, Zimerman A, Vaduganathan M, Claggett BL, Packer M, Desai AS, et al. Associations between New York Heart Association classification, objective measures, and long-term prognosis in mild heart failure: A secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2023; 8: 150–158. https://doi.org/10.1001/jamacardio.2022.4427 10.1001/jamacardio.2022.4427 PubMedWeb of Science®Google Scholar 20Greene SJ, Butler J, Spertus JA, Hellkamp AS, Vaduganathan M, DeVore AD, et al. Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction. JAMA Cardiol. 2021; 6: 522–531. https://doi.org/10.1001/jamacardio.2021.0372 10.1001/jamacardio.2021.0372 PubMedWeb of Science®Google Scholar 21Cosiano MF, Vista A, Sun JL, Alhanti B, Harrington J, Butler J, et al. Comparing New York Heart Association class and patient-reported outcomes among patients hospitalized for heart failure. Circ Heart Fail. 2023; 16:e010107. https://doi.org/10.1161/CIRCHEARTFAILURE.122.010107 10.1161/CIRCHEARTFAILURE.122.010107 PubMedWeb of Science®Google Scholar 22Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc Res. 2022; 118: 3272–3287. https://doi.org/10.1093/cvr/cvab077 10.1093/cvr/cvac013 CASWeb of Science®Google Scholar Citing Literature Volume25, Issue7July 2023Pages 929-932 ReferencesRelatedInformation